Cochrane Review Finds Anti-Amyloid Alzheimer's Drugs Lack Meaningful Clinical Benefit

What Happens Next

• →Insurers and public health systems (e.g., CMS in the US) face renewed pressure to restrict or deny coverage for lecanemab and donanemab, citing the Cochrane findings as evidence against clinical meaningfulness, which compresses revenue projections for Eisai, Biogen, and Eli Lilly.
• →The 2024 retraction of the foundational 2006 Nature paper triggers institutional reviews and potential retractions of hundreds of downstream studies built on the manipulated amyloid-cascade data, eroding credibility of amyloid-focused academic departments.
• →FDA and EMA face political and scientific pressure to tighten surrogate-endpoint standards for neurodegenerative disease approvals, requiring future Alzheimer's drug candidates to demonstrate functional improvement rather than amyloid plaque reduction alone.

Near-term: Within 1-3 months, payer negotiations for lecanemab and donanemab face headwinds as health technology assessment bodies in Europe and CMS in the US cite the Cochrane review to justify coverage restrictions, pressuring Eisai and Lilly share prices. Long-term: Over 2-5 years, regulatory agencies institutionalize stricter clinical-benefit thresholds for neurodegenerative drug approvals, accelerating capital flows toward tau-targeting, neuroinflammation, and metabolic-dysfunction hypotheses as the dominant Alzheimer's research paradigms.